Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
暂无分享,去创建一个
Thomas LaFramboise | Levi A Garraway | Kwok-Kin Wong | Matthew Meyerson | Gregory S Turenchalk | J H Leamon | William R Sellers | Hidefumi Sasaki | J. Rothberg | J. Leamon | J. Simons | M. Meyerson | W. Sellers | Jeffrey C. Lee | L. Garraway | M. Egholm | P. Jänne | E. Nickerson | M. Ronan | H. Greulich | Roman K. Thomas | R. Debiasi | T. LaFramboise | Kwok-Kin Wong | K. Shah | H. Sasaki | A. Borrás | P. Alvarez | W. Brockman | N. Lindeman | B. Desany | K. Dragnev | T. Tengs | Y. Yuza | K. O'Neill | E. J. Gutmann | Tzu-Hsiu Chen | K. Glatt | C. Lubeski | S. Hutchison | G. Turenchalk | Pasi A Jänne | Michael Egholm | Brian Desany | Jonathan M Rothberg | Konstantin H Dragnev | Torstein Tengs | Tzu-Hsiu Chen | Neal Lindeman | Heidi Greulich | Yuki Yuza | Roman K Thomas | Kinjal Shah | William Brockman | Elizabeth Nickerson | Jan F Simons | Jeffrey C Lee | Keith O'Neill | Ana M Borras | Edward J Gutmann | Ralph DeBiasi | Karen A Glatt | Christine K Lubeski | Pablo Alvarez | Stephen K Hutchison | Michael T Ronan | A. Borras | E. Gutmann | Kwok-kin Wong | Tzu Hsiu Chen
[1] C. Sawyers,et al. Targeted cancer therapy , 2004, Nature.
[2] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Meyerson,et al. A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening , 2006, Clinical Cancer Research.
[4] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[5] James R. Knight,et al. Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.
[6] G. van Ommen. The Human Genome Project and the future of diagnostics, treatment and prevention , 2002, Journal of inherited metabolic disease.
[7] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[8] E. Bakker,et al. The human genome project and the future of diagnostics, treatment, and prevention , 1999, The Lancet.
[9] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[10] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[11] Patricia L. Harris,et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] William C Hahn,et al. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.
[13] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[14] Patricia L. Harris,et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[16] C. García-Girón,et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] F. Sanger,et al. DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[18] M. Ronaghi,et al. A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.
[19] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.